The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease

British Journal of Surgery

Volumn 93, Issue 5, 2006, Pages 577-581

  Vig, S ^a,b   Chitolie, A ^a   Bevan, D ^a   Dormandy, J ^a   Thompson, M M ^a   Halliday, A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUPUS ANTICOAGULANT; MUTANT PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANKLE BRACHIAL INDEX; ANTITHROMBIN DEFICIENCY; ARTICLE; DEMOGRAPHY; DIET RESTRICTION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SCREENING; SYMPTOM; THROMBOPHILIA;

AGED; BLOOD COAGULATION FACTOR INHIBITORS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; PERIPHERAL VASCULAR DISEASES; PREVALENCE; PROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 33646478902     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5300     Document Type: Article

References (39)

1. Collins GJ Jr, Heymann RL, Zajtchuk R. Hypercoagulability in patients with peripheral vascular disease. Am Journal Surg 1975; 130: 2-6.
2. Flinn WR, McDaniel MD, Yao JS, Fahey VA, Green D. Antithrombin III deficiency as a reflection of dynamic protein metabolism in patients undergoing vascular reconstruction. J Vasc Surg 1984; 1: 888-895.
3. Eldrup-Jorgensen J, Flanigan DP, Brace L, Sawchuk AP, Mulder SG, Anderson CP et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg 1989; 9: 334-341.
4. Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg 1990; 11: 825-831.
5. Ray SA, Rowley MR, Bevan DH, Taylor RS, Dormandy JA. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction. Eur J Vasc Endovasc Surg 1997; 13: 363-370.
6. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg 1996; 23: 46-52.
7. Sampram ESK, Lindblad B. The impact of factor V mutation on the risk of occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg 2001; 22: 134-138.
8. Curi MA, Skelly CL, Baldwin ZK, Woo DH, Baron JM, Desai TR et al. Long-term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability. J Vasc Surg 2003; 37: 301-306.
9. Lee RW, Taylor LM Jr, Landry GJ, Goodnight SH, Moneta GL, Edwards JM et al. Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies. J Vasc Surg 1996; 24: 524-533.
10. Currie IC, Wilson YG, Scott J, Day A, Stansbie R, Baird RN et al. Homocysteine: an independent risk factor for the failure of vascular intervention. Br J Surg 1996; 83: 1238-1241.
11. Irvine C, Wilson YG, Currie IC, McGrath C, Scott J, Day A et al. Hyperhomocysteinaemia is a risk factor for vein graft stenosis. Eur J Vasc Endovasc Surg 1996; 12: 304-309.
12. Burns PJ, Mosquera DA, Bradbury AW. Prevalence and significance of thrombophilia in peripheral arterial disease. Eur J Vasc Endovasc Surg 2001; 22: 98-106.
13. Mireskandari M, Schachter M, Timms IG, Sever P, Wolfe JHN. Plasma homocysteine is an independent risk factor for vein graft stenosis. Br J Surg 1998; 85(Suppl 1): 27 (abstract).
14. Alving BM. The hypercoagulable states. Hosp Pract 1993; 28: 109-121.
15. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
17. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20110A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78: 1430-1433.
18. Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: A prospective, controlled analysis. J Vasc Surg 1996; 23: 53-63.
19. Evans SM, Brittenden J, Adam DJ, Ludlam C, Bradbury AW. Prevalence and significance of thrombophilia in patients with intermittent claudication. Br J Surg 1999; 86: 702-703 (abstract).
20. Aronson DC, Ruys T, van Bockel JH, Briet E, Brommer EJ, Gevers Leuven JA et al. A prospective survey of the risk factors in young adults with arterial occlusive disease. Eur J Vasc Surg 1989; 3: 227-232.
21. Levy PJ, Gonzalez MF, Hornung CA, Chang WW, Haynes JL, Rush DS. A prospective evaluation of the atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity disease. J Vasc Surg 1996; 23: 36-45.
22. Taylor LM Jr, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM. Antiphospholipid antibodies in vascular surgery patients. A cross sectional study. Ann Surg 1994; 220: 544-551.
23. Lam EY, Taylor LM Jr, Landry GJ, Porter JM, Moneta GL. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg 2001; 33: 976-982.
24. Thiagarajan P, Pengo V, Shapiro SS. The use of dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874.
25. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
26. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
27. Woodhams BJ. The simultaneous measurement of total and free protein S by ELISA. Thromb Res 1988; 50: 213-220.
28. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
29. Still RA, McDowell IF. ACP Broadsheet No. 152: March 1998. Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Path 1998; 51: 183-188.
30. Kang SS, Wong PWK, Malinow R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-298.
31. Refsum H, Fiskerstrand T, Guttormsen AB, Veland PM. Assessment of homocysteine status. J Inherit Metab Dis 1997; 20: 286-294.
32. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-538.
33. Ray SA, Rowley MR, Loh A, Talbot SA, Bevan DH, Taylor RS et al. Hypercoagulable states in patients with leg ischaemia. Br J Surg 1994; 81: 811-814.
34. Vig S, Chitolie A, Sleight S, Bevan D, Dormandy J, Thompson MM et al. Prevalence and risk of thrombophilia defects in vascular patients. Eur J Vasc Endovasc Surg 2004; 28: 124-131.
35. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338: 1009-1015.
36. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
37. Fermo I, Vigano D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
38. Caldwell S, McCarthy M, Martin SC, Hilton AC, Bartlett WA, Jones AF et al. Hyperhomocysteinaemia, peripheral vascular disease and neointimal hyperplasia in elderly patients. Br J Surg 1998; 85: 709 (abstract).
39. TransAtlantic Inter-Society Consensus (TASC) Working Group. Management of peripheral arterial disease. Int Angiology 2000; 19(Suppl 1): 65-72.